{"id":33696,"date":"2022-10-06T14:40:34","date_gmt":"2022-10-06T13:40:34","guid":{"rendered":"https:\/\/touchendocrinology.com\/?post_type=media_gallery&#038;p=33696"},"modified":"2023-02-16T11:03:18","modified_gmt":"2023-02-16T11:03:18","slug":"timothy-garvey-easd-2022-the-risk-of-developing-type-2-diabetes-in-people-with-obesity","status":"publish","type":"media_gallery","link":"https:\/\/touchendocrinology.com\/diabetes\/conference-hub\/timothy-garvey-easd-2022-the-risk-of-developing-type-2-diabetes-in-people-with-obesity\/","title":{"rendered":"Timothy Garvey, EASD 2022: The risk of developing type 2 diabetes in people with obesity"},"content":{"rendered":"<p><span style=\"font-weight: 400\">Obesity is the leading risk factor for type 2 diabetes. Obesity causes increased levels of fatty acids and inflammation, leading to insulin resistance.\u00a0In this touchENDOCRINOLOGY interview, <strong>Prof.\u00a0Timothy Garvey<\/strong> (University of Alabama, Birmingham, AL, USA) discusses this risk of developing type 2 diabetes in people with obesity.<\/span><\/p>\n<p>The abstract entitled: \u2018Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity&#8217;<em>\u00a0<\/em>was presented at the <a href=\"https:\/\/www.easd.org\/annual-meeting\/easd-2022.html\" rel=\"nofollow noopener\" target=\"_blank\">European Association for the Study of Diabetes<\/a>, 19-23 Sept, 2022.<\/p>\n<p><strong>Questions:<\/strong><\/p>\n<ol>\n<li>What is known about the risk of developing type 2 diabetes in people with obesity? (0:22)<\/li>\n<\/ol>\n<p><span style=\"font-weight: 400\"><strong>Disclosures:<\/strong> Timothy Garvey discloses grant\/research support from Eli Lilly, Epitomee, Novo Nordisk, Pfizer.<\/span><\/p>\n<p><strong>Support:<\/strong> Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.<\/p>\n<p><em><strong>Recorded as a highlight of EASD 2022<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Obesity is the leading risk factor for type 2 diabetes. Obesity causes increased levels of fatty acids and inflammation, leading to insulin resistance.\u00a0In this touchENDOCRINOLOGY interview, Prof.\u00a0Timothy Garvey (University of Alabama, Birmingham, AL, USA) discusses this risk of developing type 2 diabetes in people with obesity. The abstract entitled: \u2018Semaglutide 2.4 mg reduces the 10-year [&hellip;]<\/p>\n","protected":false},"featured_media":33738,"template":"","class_list":["post-33696","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-diabetes","vocabulary_1-obesity","video_categories-easd-highlights"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media_gallery\/33696"}],"collection":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":5,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media_gallery\/33696\/revisions"}],"predecessor-version":[{"id":40647,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media_gallery\/33696\/revisions\/40647"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media\/33738"}],"wp:attachment":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media?parent=33696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}